Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent/Lilly PD-1 Approved in China for Hodgkin's Lymphoma

publication date: Dec 27, 2018

Innovent Biologics and Eli Lilly announced their co-developed PD-1 immunotherapy was approved in China as a third-line treatment for patients with classical Hodgkin's lymphoma. Tyvyt® (sintilimab) is the second China-developed anti-PD-1 mAb to be awarded marketing authorization, following Junshi's Tuoyi last week. In 2015, Innovent formed a $1 billion partnership with Lilly for multiple drug candidates including three anti-PD-1 based bispecific antibodies. Tyvyt is the first approval from that portfolio. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.